

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ranolazine
Brand Name	Corzyna™
Dosage Forms	500 mg and 1,000 mg extended-release tablets
Manufacturer	KYE Pharmaceuticals Inc.
Submission Type	New Submission
Use Reviewed	As an add-on symptomatic treatment for inadequately controlled stable angina
Common Drug Review (CDR)	Yes, CDR recommended: Do Not Reimburse . Visit the CDR website for more details: https://www.cadth.ca/ranolazine
Provincial Review	The Drug Benefit Council (DBC) does not review drugs in which the Canadian Drug Expert Committee (CDEC) recommends to not be reimbursed. As such, ranolazine was not reviewed by the DBC and the Ministry of Health's drug coverage decision is based on the CDEC recommendation and an internal review only.
Drug Coverage Decision	Non-Benefit
Date	February 1, 2022
Reasons	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none"> Based on three clinical trials, any advantages of ranolazine over placebo with respect to efficacy and health-related quality of life were uncertain and of unclear clinical significance. Due to limitations of the clinical evidence available for ranolazine, the cost-effectiveness of the drug was highly uncertain.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.